Docetaxel polymeric micelle (Samyang Biopharmaceuticals)

多西他赛纳米胶束 (Samyang Biopharmaceuticals)

Report date: 2025/04/29 15:44:58

Base Information

Drug NameDocetaxel polymeric micelle (Samyang Biopharmaceuticals)
Drug Alias Name多西他赛-PMDocetaxel-PMNanoxelMB-5704SYP-0704A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsHead and Neck Neoplasms +[4] 
Global Approved IndicationsUrinary Bladder NeoplasmsHead and Neck Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2016/07/01
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamyang Biopharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesSamyang Biopharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsHead and Neck Neoplasms
Inactive IndicationsSolid tumoursSquamous Cell Carcinoma of Head and Neck

Other Information

ATC CodeL01CD02
Related LinksN/A